Skip to main content
    S

    Serina Therapeutics Inc (SER)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.42
    +0.03 (+2.16%)

    Market Cap: $36.93M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Serina Therapeutics Inc (SER) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Serina Therapeutics reported revenue of $130.00K for the fiscal year ended Dec 31, 2025, up 132.1% from the year before. That year, net income was -$19.21M with a net margin of -14780.8%, operating cash flow was -$17.95M and free cash flow was -$18.01M. The quarter ended Sep 30, 2026 had revenue of $125.00K and net income of -$7.91M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $1.67M, a compound annual decline of 24.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$130.00K+132.1%100.0%-18478.5%-14780.8%
    Dec 2024$56.00K-98.2%100.0%-30442.9%-20012.5%
    Dec 2023$3.15M+9173.5%100.0%-99.2%167.1%
    Dec 2022$34.00K-76.4%61.8%-20514.7%-30947.1%
    Dec 2021$144.00K-60.1%86.8%-5509.0%-6031.3%
    Dec 2020$361.00K-79.1%92.8%-2797.8%-3040.4%
    Dec 2019$1.73M+23.8%85.9%-726.8%-716.7%
    Dec 2018$1.40M-0.6%73.9%-805.5%-553.8%
    Dec 2017$1.40M-15.7%88.0%-474.6%-472.7%
    Dec 2016$1.67MN/A45.3%-764.6%-929.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$130.00K$56.00K$3.15M$34.00K$144.00K$361.00K$1.73M$1.40M$1.40M$1.67M
    Cost of revenue$0$0$0$13.00K$19.00K$26.00K$244.00K$364.00K$168.00K$911.00K
    Gross profit$130.00K$56.00K$3.15M$21.00K$125.00K$335.00K$1.48M$1.03M$1.24M$755.00K
    Research and development$13.15M$7.48M$2.39M$1.02M$1.46M$3.71M$5.90M$6.63M$5.78M$7.87M
    Operating income-$24.02M-$17.05M-$3.13M-$6.97M-$7.93M-$10.10M-$12.56M-$11.24M-$6.66M-$12.74M
    Net income-$19.21M-$11.21M$5.27M-$10.52M-$8.69M-$10.98M-$12.38M-$7.73M-$6.64M-$15.49M
    EBITDA-$18.85M-$10.14M$5.92M-$3.92M-$6.24M-$8.25M-$11.26M-$10.53M-$5.93M-$11.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$125.00K$0$0$0$0$130.00K$0-$14.00K$14.00K$51.00K$5.00K$3.09M
    Gross profit$125.00K$0$0-$23.00K$0$130.00K$0-$14.00K$14.00K$51.00K$5.00K$3.09M
    Operating income-$7.86M-$6.78M-$6.28M-$6.21M-$6.39M-$5.57M-$5.86M-$5.55M-$5.31M-$3.87M-$2.32M$241.00K
    Net income-$7.91M-$6.36M-$6.90M-$3.34M-$4.59M-$6.46M-$4.82M-$2.75M$1.38M$5.18M-$15.02M$1.05M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $2.95M by $110.00K. Shareholder equity was negative, at -$37.00K, as total liabilities of $6.99M exceeded total assets of $6.95M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$6.95M$6.72M$8.97M$3.24M$3.15M$3.92M$7.44M$10.67M$9.63M$3.22M
    Current assets$6.08M$5.68M$7.62M$2.45M$2.23M$2.28M$4.05M$7.85M$7.59M$688.00K
    Cash and equivalents$3.06M$3.67M$7.62M$645.00K$584.00K$527.00K$2.35M$6.71M$7.38M$259.00K
    Total liabilities$6.99M$6.22M$4.86M$20.56M$15.03M$9.32M$4.83M$2.44M$1.31M$25.60M
    Short-term debt$0$193.00K$3.67M$7.65M$7.14M$436.00K$0N/AN/AN/A
    Long-term debt$2.95M$0$2.98M$10.48M$6.06MN/AN/AN/AN/AN/A
    Shareholder equity-$37.00K$641.00K-$32.29M-$17.21M-$11.83M-$5.12M$2.22M$7.45M$7.28M-$23.42M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$21.87M$25.81M$27.30M$6.95M$12.41M$8.94M$6.73M$6.72M$7.43M$10.71M$10.86M$8.97M
    Total liabilities$7.95M$7.08M$9.67M$6.99M$10.82M$7.29M$5.17M$6.22M$21.26M$27.10M$15.16M$4.86M
    Cash and equivalents$19.40M$23.02M$24.53M$3.06M$8.62M$6.04M$4.27M$3.67M$3.19M$6.06M$8.71M$7.62M
    Shareholder equity$13.92M$18.73M$17.63M-$37.00K$1.76M$1.80M$1.70M$641.00K-$13.77M-$16.36M-$4.31M$4.11M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$17.95M-$17.14M-$2.48M-$5.94M-$7.86M-$7.82M-$10.16M-$8.00M-$6.29M-$8.43M
    Capital expenditures$59.00K$22.00K$504.00K$9.68K$108.43K$20.00K$641.00K$21.00K$1.00K$23.00K
    Free cash flow-$18.01M-$17.16M-$2.98M-$5.95M-$7.96M-$7.84M-$10.80M-$8.02M-$6.29M-$8.45M
    Investing cash flow-$59.00K-$22.00K-$504.00K$0$666.00K-$20.00K-$361.00K$1.33M$5.00K-$28.00K
    Financing cash flow$17.41M$13.21M$10.07M$6.00M$7.25M$5.96M$6.26M$6.00M$13.28M$7.25M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.50M-$6.68M-$4.57M-$6.03M-$3.85M-$3.75M-$4.32M-$4.59M-$2.96M-$8.01M-$1.58M$121.00K
    Capital expenditures$3.00K$28.00K$25.00K$59.00K$13.00K$46.00K$0$5.00K$3.00K$0$14.00K$70.00K
    Free cash flow-$5.50M-$6.71M-$4.59M-$6.09M-$3.86M-$3.80M-$4.32M-$4.59M-$2.96M-$8.01M-$1.59M$51.00K
    Last 12 quarters

    Frequently Asked Questions About SER

    What is Serina Therapeutics' annual revenue?

    Serina Therapeutics reported revenue of $130.00K for the fiscal year ended Dec 31, 2025.

    How fast is Serina Therapeutics' revenue growing?

    Revenue was up 132.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 56.4%.

    Is Serina Therapeutics profitable?

    No. Serina Therapeutics reported net income of -$19.21M for the fiscal year ended Dec 31, 2025, with a net margin of -14780.8%.

    How much free cash flow does SER generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$17.95M minus capital expenditures of $59.00K produced free cash flow of -$18.01M.

    How much debt does Serina Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $2.95M, short-term debt of $0 and cash and equivalents of $3.06M.